So relatable.

📢From our current issue: gaps in diversity amongst investigators in TROG clinical trials 👉Only 1 in 5 trials led by female principal investigators 👉Only 1 in 3 trials led by female chief investigators ow.ly/6YnI50Qa85Z

Lovely work from Shalini Subramaniam Patients' perception of the benefits of palliative systemic therapy for advanced cancer - Subramaniam - 2024 - Internal Medicine Journal - Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/im… Belinda Kiely martinst

When CALD patients say no thanks to treatment. The Road Less Traveled: Perspective From an Australian Oncologist | JCO Global Oncology ascopubs.org/doi/10.1200/GO… #JCOGO JCO Global Oncology South Western Sydney Local Health District

Oh hello Chicago! Haven’t seen you in a while. #ASCO2024

New conference, same old game #ASCO24

I have no questions to ask 😆

Now at #ASCO24: In the phase 3 FRUTIGA trial, the multi anti-VEGFR inhibitor #fruquintinib + chemotherapy significantly extended progression-free survival, but not overall survival, as 2L therapy in patients with advanced #GastricCancer or #GEJCancer doi.org/10.1038/s41591…

CHECKMATE 8HW 👉excited about option of nivo/ipi as 1L SOC for MSI-H/ dMMR mCRC 👉24 month PFS2 -> 83% 👉but how does it compare to KEYNOTE 177 pembro? 👉excitedly awaiting the nivo arm #ASCO2024 #crcsm OncoAlert

NEOPRISM-CRC & IBI310 👉Starting to shift landscape for neoadjuvant treatment for MSI-H/ dMMR colon cancer Raises so many questions: 🤔Can we avoid surgery? 🤔Is pCR surrogate for cure? 🤔Choice and length of IO? #ASCO2024 #crcsm OncoAlert

ESOPEC 👉Median OS 66 m FLOT vs 37 m CROSS 👉pCR 17% FLOT vs 10% CROSS 🤔How would adj nivo change results? 🤔I would pick FLOT over CROSS, but maybe I can have both? 🤔Perhaps best outcome: Chemotherapy -> CRT -> surgery -> adj IO Not end of story. #ASCO2024 #crcsm OncoAlert

And now... updated results of 41 patients CURATIVELY treated with 6m of Dostarlimab (PD-1) WITHOUT ☢️or🔪 ✅100% cCR rate ✅0 Local or distance relapses ✅Sustained cCR for > 12 m seen in 20 patients with mFU of 29 m THIS. IS. AWESOME #ASCO24

Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer #ASCO24 👉100% cCR, no relapse & no additional therapy 👉20 pts with sustained response of 12mo 👉ctDNA as an early marker of response 🧐Just amazing efficacy… ESMO - Eur. Oncology

“Biology continues to be the king, and selection the queen” — David Chang discussing old tools and new tricks in pancreas cancer #ASCO2024 #crcsm

🔥off the press: An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202 ESMO Open 👉Median follow-up 45.4 mo 👉ORR 37.0% 👉mDOR 9.1 mo 👉mPFS 7 mo 👉mOS 17.5 m 👇my personal author share link: authors.elsevier.com/sd/article/S20… ESMO - Eur. Oncology EASLnews ILCA

A privilege to chat with Dr Lidia Schapira Stanford Medicine for JCO Cancer Stories podcast JCO Global Oncology South Western Sydney Local Health District And a lovely way to end #ASCO2024 which focused on ‘The art and science of cancer care - from comfort to cure’ ascopubs.org/do/road-less-t… #ArtOfOncology

Dr Vanessa Wong and team had their abstract published as part of the 2024 ASCO Annual meeting this week in Chicago 🌟 🔍 A high proportion of Australian patients with metastatic colorectal cancer undergo testing for genetic mutations (mismatch repair testing).

The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer mdpi.com/2905242 IJMS MDPI 👉CDX2 is prognostic in CRC 👉larger studies required to confirm predictive utility in left-sided & rectal cancers Tara Roberts Western Sydney University Ingham Institute for Applied Medical Research South Western Sydney Local Health District

🎉 Thrilled to share that an ONJ Cancer Research Institute and La Trobe University led project has been awarded $5 million from the NHMRC, to investigate treatment resistance in colorectal cancer. Congratulations to Prof John Mariadason, Dr Lisa Mielke and collaborators! Read more 👉 lnkd.in/gNNMtYS2

This Medical Life podcast New episode out now: Episode 73 Colorectal Cancer (Part 3) | Management Our guests include Dr Stephanie Lim (Oncologist), Dr Meredith Johnston (Radiation Oncologist) and Dr Emilia Ip (Genetist) Available on all podcasting services & Spotify